ABSTRACT
Introduction
The incidence of anal cancer in HIV-infected and HIVnegative men who have sex with men (MSM) is increasing [1] [2] [3] . The occurrence of high-grade anal dysplasia and anal cancer is strongly associated with HIV infection, a history of receptive anal intercourse and anogenital human papillomavirus (HPV) infection [3] [4] [5] [6] [7] [8] [9] .
Introduction of the cervical cancer screening program resulted in a decrease in cervical cancer incidence rates in Western countries from 45 per 100,000 person-years to 8 per 100,000 person-years [10] . It is because of this successful methodology that screening programmes for anal dysplasia are advocated. The hallmark of cervical cancer screening is the Pap smear, which enables cytological examination of exfoliated cells [11] . Patients with abnormal cervical cytology are referred for further evaluation with cervical colposcopy. However, sensitivity of cytology is not optimal. The sensitivity of atypical squamous cells of undetermined significance (ASCUS) cervical cytology can be greatly improved with the introduction of HPV DNA testing using the Hybrid Capture II (HCII) assay for the detection of high-risk HPV strains [12] [13] [14] [15] . Although HCII testing is not yet FDA approved for use in the anal canal, it has been shown to improve the ability to predict high-grade dysplasia in MSM with ASCUS cytology. Referring only those with ASCUS and high-risk HPV genotypes for anoscopy prevents unnecessary diagnostic procedures in this group [16] .
We investigated the prevalence of anal dysplasia in a group of HIV-infected MSM using clinician-collected anal cytology and HPV DNA testing compared to findings on anoscopy with biopsy. The adequacy of the different screening methods was determined. The findings of this study could be used to determine the best future screening strategy for anal dysplasia in HIV-infected MSM. tient clinic of the Slotervaart Hospital, Amsterdam, the Netherlands. HIV-infected MSM were asked to participate. All patients provided written informed consent before inclusion in the study. Inclusion started in March 2008. Demographic and clinical information was collected by using a standardized questionnaire or was retrieved from the patient's medical file. In each patient who consented with anoscopy a clinician-collected anal swab was taken for cytological examination and HPV DNA testing. The study was approved by the Institutional Review Board.
Anal Cytology
The clinician-collected anal cytology sample was acquired through inserting a cytobrush 5 cm into the anal canal. The cytobrush was removed while rotating 360 degrees and pressing to the wall of the anal canal. The collected sample was fixed in 1.5 ml of Surepath preservative fluid (Becton Dickinson, USA) for liquid-based cytology and HPV testing. Preparations were produced analogous to thin layer liquid based cervical cytology using Autocyte (Autocyte, Tripath Imaging Inc, Burlington, USA).
Anoscopy
Anoscopy was done with the use of a conventional gynaecologic colposcope. All exams were performed by or under direct supervision of one single experienced gastroenterologist during the whole study period. At first a digital anorectal examination was performed. An anal cytology sample was collected as described in the previous paragraph. Thereafter a 3% acetic acid solution was locally applied by inserting and rotating a soaked wooden cotton-tipped swab. A second swab with acetic acid was inserted and left in place for one minute. Next, the proctoscope was introduced to inspect the anal canal. The acetowhite areas and the areas with a suspicious appearance were biopsied. In case of no suspected area, no biopsies were taken.
Biopsy and Anal Swab Sample Preparation
All cytological and histological preparations and specimens were examined by two experienced pathologists. Cellular changes were determined using standard criteria for gynaecologic cytology in accordance with the Bethesda system [17] . Cytological specimens were classified as normal, ASCUS, low-grade squamous intraepithelial lesion (LSIL), or high-grade squamous intraepithelial lesion (HSIL). Histological specimens were classified as normal, anal intraepithelial neoplasia (AIN) grade 1, AIN grade 2, AIN grade 3, or squamous cell carcinoma (SCC).
HPV DNA Testing
After processing the anal swab sample for cytological examination the remainder of the sample was sent to the Molecular Biology Department for HPV DNA testing. All samples were stored at 5°C until further processing. After DNA isolation, HPV DNA was amplified by the SPF10 PCR primer set (Innogenetics, Gent, Belgium). Test characteristics and reaction conditions have been described Before, [18] from 43 patients enough material was available to be analyzed on the presence of high risk HPV DNA using the HCII test (Qiagen, Hilden, Germany).
Results
The results of 58 HIV-infected MSM are presented here. The patient characteristics are shown in Table 1 . The mean age was 44.8 years (± 9.4), 85% was using combined antiretroviral therapy, 71% had a HIV viral load below 40 copies/ml, and 57% reported receptive anal intercourse in the last 6 months. Table 2 outlines the results of the clinician-collected anal swab samples as compared to the findings on anoscopy. Specimen adequacy for cytological specimens was high (53/58, 91%). In 34 (63%) of anal swab samples any grade of dysplasia was observed compared to 41 (71%) of biopsy specimens. The cytology specimens revealed high-grade dysplasia in 4 (7%) participants compared to 29 (50%) of biopsy specimens. The agreement between findings on cytology and histology was poor (kappa 0.20). No significant association between CD4 cell count, HIV viral load, receptive anal intercourse in the last 6 months, treatment for sexually transmitted diseases in the last year or smoking and any grade of anal dysplasia was observed.
The high-risk HPV prevalence in the cytology specimens was 90%. All patients infected with HPV DNA harboured a median number of 2 (range 0 -7) high-risk HPV types (data not shown). In the 43 samples that were analyzed with both the SPF10 PCR and the HCII assay identical test results for the presence or absence of high-risk HPV types were found in 35 patients (81%).
Discussion
In the study presented here we evaluated different aspects of a screening programme for anal dysplasia in HIV-infected MSM. Cytological findings and HPV DNA testing results on clinician-collected cytology specimens were compared to histological findings.
The HPV prevalence in our study population was high and infections with multiple high-risk HPV types were common. The high HPV prevalence and detection of multiple HPV genotypes is in accordance with previous studies in HIV-infected MSM [19] [20] [21] [22] [23] . Due to the very high HPV prevalence found with both the SPF10 PCR and HCII assay as HPV DNA testing methods, HPV DNA testing lacks specificity to detect anal dysplasia in this specific patient population. A high prevalence of any grade of dysplasia was observed in both cytology and histology specimens. No data on sensitivity and specificity were calculated because biopsies were not done in every patient and the patient number is too low to perform any statistical analysis on. The observed agreement between findings on cytology and histology was poor. Cytological testing was complicated by a generally low cell yield. Furthermore, inadequate sampling of the transformation zone due to blind sampling could lead to an incorrect classification of dysplasia on cytology. This is also reflected in the high proportion of ASCUS cytology. In 44% of clinician-collected cytological samples ASCUS was reported. Other studies showed incidence rates of ASCUS cytology in the anal canal of 14% -78% in HIV-infected MSM. These studies indicated that the incidence of ASCUS cytology in the anal canal is higher than in the cervix [16, 23, 24] . Adding the HCII assay in case of ASCUS cytology, as is currently done for ASCUS on cervical cytology, could improve the clinical sensitivity to detect anal dysplasia [25] [26] [27] . However, in this study the HPV prevalence when using the HCII assay was still 81% so adding this assay would not improve clinical sensitivity.
In two large studies on anal cancer screening in HIV-infected patients, in a predominantly male HIVinfected population, anal cytology and HPV DNA detection have high sensitivity but low specificity for detecting high-grade anal dysplasia [23, 28] . In the study presented here patients with high-grade dysplasia were referred for treatment to a surgeon with experience in the field of anal surgery. If patients refused referral for treatment a follow-up anoscopy was scheduled in a year. All patients without a treatment indication were scheduled to repeat anal cytology and HPV testing in two years followed by anoscopy. A more strict screening algorithm was suggested by Goldstone et al. [29] . The guidelines from the European AIDS Clinical Society (EACS) recommend a digital rectal exam with or without Pap smear testing with a screening interval of 1 -3 years [30] .
The considerable prevalence of high-grade dysplasia on anoscopy with biopsy calls for a routine screening program for anal dysplasia in HIV-infected MSM. However, the optimal screening strategy to limit the amount of patients requiring anoscopy needs to be determined still. Testing for HPV DNA using the HCII assay lacked clinical sensitivity as over 80% of participants were HPV-infected. Self-collected anal cytology could be a promising sampling method, but the availability of anoscopy and trained physicians is a prerequisite in the implementation of a screening program on anal dysplasia, because as it currently stands almost all patient require anoscopy. In agreement with our results, a study has been done assessing cost-effectiveness of high-resolution anoscopy (HRA), anal cytology, and anal HPV detection in screening for AIN2/3 in HIV-positive MSM. The direct use of HRA is the most cost-effective strategy for detecting AIN2/3 in HIV-infected MSM [31] .
In conclusion, the prevalence of anal HPV infection and anal dysplasia on cytological and histological samples in HIV-infected MSM is high. The agreement between cytology and histology results is poor. Given the high HPV prevalence HPV DNA testing should not be routinely applied in this specific patient population of MSM. Screening should include anoscopy. Finally, follow-up is essential to improve our knowledge on the natural course of anal dysplasia and to determine the optimal screening interval.
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